Apyx Medical Q2 FY26 net loss narrows to $3.2 million; revenue rises 22.1% to $13.9 million vs year ago
Reuters2026/08/06 21:04- Apyx Medical posted Q2 2026 revenue up 22.1% to $13.9 million, led by Surgical Aesthetics up 28.1% to $12.4 million.
- Net loss attributable to stockholders narrowed to $3.2 million; loss per share improved to $0.07.
- Adjusted EBITDA loss (non-GAAP) narrowed to $0.7 million as gross margin rose 1.6 percentage points to 63.9%.
- Expanded FDA 510(k) clearance added power liposuction for AYON; limited launch began, with initial commercial shipments in June 2026.
- Reaffirmed FY2026 revenue outlook of $59 million-$60 million, including Surgical Aesthetics $54 million-$55 million and OEM about $5 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The 10-year U.S. Treasury yield climbs to 4.8%, erasing the dividend advantage of utility stocks; the sector’s rebound depends on interest rate stabilization rather than technical signals.
As U.S. Treasury yields continue to climb, the American utilities sector is experiencing a significant pullback—a rise in yields not only erodes the relative appeal of the sector’s dividends but also raises financing costs for the most capital-intensive industries within this market.
Euro holds gains above 1.1600 despite robust US jobs data, traders eye ECB rate decision
Port of Tauranga wins fast-track approval for Stella Passage development
Crypto prices
More
